Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | oxidoreductase | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | flap endonuclease-1 | 0.0089 | 0.8501 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.003 | 0 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.003 | 0 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 1 | 1 |
Trichomonas vaginalis | flap endonuclease-1, putative | 0.0089 | 0.8501 | 1 |
Giardia lamblia | Flap structure-specific endonuclease | 0.0089 | 0.8501 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.003 | 0 | 0.5 |
Toxoplasma gondii | flap structure-specific endonuclease 1, putative | 0.0089 | 0.8501 | 1 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.003 | 0 | 0.5 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.003 | 0 | 0.5 |
Plasmodium vivax | DNA repair protein RAD2, putative | 0.0078 | 0.6848 | 0.8055 |
Leishmania major | flap endonuclease-1 (FEN-1), putative | 0.0089 | 0.8501 | 1 |
Schistosoma mansoni | flap endonuclease-1 | 0.0077 | 0.671 | 0.671 |
Echinococcus granulosus | flap endonuclease 1 | 0.0089 | 0.8501 | 1 |
Plasmodium falciparum | flap endonuclease 1 | 0.0089 | 0.8501 | 1 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.003 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.003 | 0 | 0.5 |
Trypanosoma brucei | flap endonuclease-1 (FEN-1), putative | 0.0089 | 0.8501 | 0.8501 |
Schistosoma mansoni | xp-G/rad2 DNA repair endonuclease family | 0.0078 | 0.6848 | 0.6848 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.003 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.003 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0078 | 0.6848 | 0.8055 |
Echinococcus multilocularis | DNA repair protein complementing XP G cells | 0.0078 | 0.6848 | 0.8055 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.003 | 0 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.003 | 0 | 0.5 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.003 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.003 | 0 | 0.5 |
Echinococcus granulosus | DNA repair protein complementing XP G cells | 0.0078 | 0.6848 | 0.8055 |
Brugia malayi | Flap endonuclease-1 | 0.0089 | 0.8501 | 1 |
Trypanosoma cruzi | flap endonuclease-1 (FEN-1), putative | 0.0089 | 0.8501 | 1 |
Chlamydia trachomatis | monooxygenase | 0.003 | 0 | 0.5 |
Echinococcus multilocularis | flap endonuclease 1 | 0.0089 | 0.8501 | 1 |
Toxoplasma gondii | XPG N-terminal domain-containing protein | 0.0078 | 0.6848 | 0.8055 |
Entamoeba histolytica | Flap nuclease, putative | 0.0089 | 0.8501 | 1 |
Plasmodium falciparum | DNA repair protein RAD2, putative | 0.0078 | 0.6848 | 0.8055 |
Plasmodium vivax | flap endonuclease 1, putative | 0.0089 | 0.8501 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.003 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.003 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 5 uM | Antiproliferative activity against HMEC1 cells by SRB assay | ChEMBL. | 18078313 |
IC50 (functional) | > 5 uM | Antiproliferative activity against human HL60 cells by SRB assay | ChEMBL. | 18078313 |
IC50 (functional) | > 5 uM | Antiproliferative activity against human A459 cells by SRB assay | ChEMBL. | 18078313 |
IC50 (functional) | > 5 uM | Antiproliferative activity against human HL60 cells by SRB assay | ChEMBL. | 18078313 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 18078313 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.